BioVie Inc

NASDAQ:BIVIUnited States

BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Contact Information

Headquarters

680 W NYE LANE, SUITE 201CARSON CITY, NV, United States 89703

Phone

775-888-3162

Fax

---

Executives

Independent Chairman of the Board

James Lang

President, Chief Executive Officer, Director

Viet Cuong Do

Chief Financial Officer, Corporate Secretary

Joanne Kim

Chief Medical Officer

Joseph Palumbo

Independent Director

Richard Berman